SEC filingsOct 12, 2026 to Oct 19, 2026: insiders reported 840 purchases and sales across 212 companies.840 insider purchases and sales in 7 daysSee the filings →
HornScout

Company profile

XENE

Xenon Pharmaceuticals Inc.
NASDAQHealth Care

Latest close: 33.49 USD · Oct 16, 2026 · 1 year · split-adjusted

On the price, the facts of the public record■Insider buy□Insider sell●Results filed
With an account, also○dividends▲splits◌next earningswith an account

End-of-day prices provided by Twelve Data · One close per session; the series does not update during the trading day.

Latest on record

The most recent facts, as filed.

Up to three of the most recent, checkable facts already loaded on this page, each linked to its source.

  1. Sep 30, 2026Reported purchase · Form 4IAN MORTIMER, PRESIDENT & CEO · $1.1MOpen the filing ↗
  2. Sep 30, 2026Reported purchase · Form 4Thomas Patrick Kelly, Chief Financial Officer · $559.7KOpen the filing ↗
  3. Aug 28, 2026Reported sale · Form 4CHRISTOPHER JOHN KENNEY, Chief Medical Officer · $383.1KOpen the filing ↗

In numbers

What this profile holds, counted.

Closes · 1 year250
SEC filings on record74013 flagged findings
Reported transactions (Form 4)80since Jan 9, 2026 · and 8 other holdings
Corporate events (8-K)30since Jun 3, 2020

What the record says

Description, identity and filings, each with its source.

Every block cites its source. The colour of a finding marks its category — which document, who filed it — not how much it matters.

SEC topics

Regulatory history

Topics detected in its SEC reports, with the original excerpt.

Each topic is assigned by a classifier over the full filing; the excerpts show where it was detected and are not always enough to verify it. Open the filing to read it in full.

  • 2026-05-07share offering or dilution eventrecentOpen filing ↗
    “…and consultants. Future stock option grants and issuances of common shares under our share-based compensation plans will result…”
    +1 more passage from the same document
    • “…Outstanding, beginning of period 2,173,081 2,173,081 Issued 877,194 — Exercised (1) ( 118,982 ) — Outstanding, end of period…”

Original excerpts from SEC filings, untranslated. Not advice and not a prediction.

SEC record

SEC dossier

What this company has filed with the SEC, in plain language.

The 25 most recent filings (of 740)

Everything filed

Every SEC filing, newest first, with what it is. Below, each type with its own explanation.

  • Insider transaction · 5 Form 4 filings newshow all 5hide
  • Aug 28, 26Form 144 ↗Notice of proposed sale
  • Aug 13, 26Form 4 ↗Insider transaction
  • Aug 13, 26Form 144 ↗Notice of proposed sale
  • Aug 13, 26SCHEDULE 13G/A ↗Passive stake · Wellington Management Group LLP · 1.5% · event on Jun 30, 26 · amendment
  • Aug 7, 26SCHEDULE 13G/A ↗Passive stake · FMR LLC · 10.3% · event on Jul 31, 26 · amendment
  • Aug 6, 2610-Q ↗Quarterly report
  • Aug 6, 268-K ↗Current report · Results · Communication to the market
  • Aug 6, 26SCHEDULE 13G/A ↗Passive stake · FMR LLC · 9.9% · event on Jun 30, 26 · amendment
  • Insider transaction · 2 Form 4 filingsshow all 2hide
  • Notice of proposed sale · 2 Form 144 filingsshow all 2hide
  • Insider transaction · 7 Form 4 filingsshow all 7hide
  • Jun 3, 268-K ↗Current report · A senior executive left or was appointed

740 filings on record, the oldest from Sep 12, 13.

Listing the 25 most recent filings of the 740 on record.

8-Ks, explained

Stress1Structure35Governance29
  • Jun 3, 26GovernanceA senior executive left or was appointed+2 more in the same filing8-K 5.02 ↗
  • Apr 13, 26GovernanceA senior executive left or was appointed+1 more in the same filing8-K 5.02 ↗
  • Mar 12, 26StructureEntered a material agreement+2 more in the same filing8-K 1.01 ↗
  • Governance4 senior executive changes2025show all 4hide
    • Dec 1, 25GovernanceA senior executive left or was appointed+1 more in the same filing8-K 5.02 ↗
    • Oct 17, 25GovernanceA senior executive left or was appointed+2 more in the same filing8-K/A 5.02 ↗
    • Oct 16, 25GovernanceA senior executive left or was appointed8-K 5.02 ↗
    • Jul 3, 25GovernanceA senior executive left or was appointed8-K 5.02 ↗
  • Mar 5, 25GovernanceAuditor change filing (8-K Item 4.01)+1 more in the same filing8-K 4.01 ↗
  • Governance3 senior executive changes2024 – 2025show all 3hide
    • Feb 27, 25GovernanceA senior executive left or was appointed+3 more in the same filing8-K 5.02 ↗
    • Jan 17, 25GovernanceA senior executive left or was appointed8-K 5.02 ↗
    • Apr 19, 24GovernanceA senior executive left or was appointed8-K 5.02 ↗
  • Nov 30, 23StructureEntered a material agreement+2 more in the same filing8-K 1.01 ↗
  • Aug 9, 23StructureCompleted an acquisition or disposal+2 more in the same filing8-K 2.01 ↗
  • Governance3 senior executive changes2022 – 2023show all 3hide
    • Aug 8, 23GovernanceA senior executive left or was appointed+1 more in the same filing8-K 5.02 ↗
    • Mar 14, 23GovernanceA senior executive left or was appointed+1 more in the same filing8-K 5.02 ↗
    • Jun 2, 22GovernanceA senior executive left or was appointed+2 more in the same filing8-K 5.02 ↗
  • Mar 22, 22StructureSold unregistered shares8-K 3.02 ↗
  • Mar 1, 22StructureEntered a material agreement+1 more in the same filing8-K 1.01 ↗
  • Jan 12, 22StructureSold unregistered shares+2 more in the same filing8-K 3.02 ↗

9 older filings not shown · The record reaches back to Nov 10, 14.

Notable in the record

Stress disclosures older than the timeline above. They are individual events from the record, not a complete timeline: there may be more between them.

  • Aug 13, 15StressPast accounts declared unreliable and being restated8-K 4.02 ↗

The full record holds 1 stress filing.

Corporate events are tracked from 2004-08-23, when the SEC renumbered 8-K items. Earlier filings use an incompatible numbering and are not classified here.

Ownership and control

Schedule 13G: short-form filing

The short form, for holders who meet specific requirements: institutional investors, passive investors without a control purpose, or exempt investors. Asset managers and index funds usually file it.

  • FMR LLC10.3%Jul 31, 26SCHEDULE 13G/A ↗2 co-filers on this document — the figure is the largest single stake, not their sum. · 3 earlier filings
  • Avoro Capital Advisors LLC6.3%Mar 31, 26SCHEDULE 13G/A ↗2 co-filers on this document — the figure is the largest single stake, not their sum.
  • BlackRock, Inc.6.2%Jun 30, 25SCHEDULE 13G ↗
  • DRIEHAUS CAPITAL MANAGEMENT LLC4.9%Dec 31, 25SCHEDULE 13G/A ↗
  • JANUS HENDERSON GROUP PLC4.5%Mar 31, 26SCHEDULE 13G/A ↗1 earlier filing
show one more holderhide
  • Wellington Management Group LLP1.5%Jun 30, 26SCHEDULE 13G/A ↗3 co-filers on this document — the figure is the largest single stake, not their sum. · 2 earlier filings

Structured 13D/G data starts 2023-12, when the SEC moved these filings to a machine-readable format. Earlier filings exist but are not parsed here.

Sale intention announced

On Aug 28, CHRISTOPHER KENNEY filed notice of intent to sell up to $438K. It is filed under a scheduled plan (10b5-1), arranged in advance.

A notice is not a sale: it may not go ahead, may happen in part, or at a different price.

After the notice, they sold $426K across 2 trades on Aug 28, per their Form 4. That is 100% of the shares announced so far, and the window is still open.

View notice (Form 144) ↗+1 more recent notices

SEC record

Insider transactions

Buys and sells reported by officers, directors and major shareholders on SEC Form 4.

Buys and sells

  • Sep 30, 26Buy$1.1MIAN MORTIMERPRESIDENT & CEO↗
  • Sep 30, 26Buy$560KThomas Patrick KellyChief Financial Officer↗
  • Aug 28, 26Sell$383KCHRISTOPHER JOHN KENNEYChief Medical Officer↗
  • Aug 28, 26Sell$43KCHRISTOPHER JOHN KENNEYChief Medical Officer↗
  • Aug 11, 26Sell$641KSTEVEN GANNON↗
  • Jun 5, 26Sell$63KGillian Cannon↗
  • Jun 5, 26Sell$70KGARY PATOU↗
  • Mar 13, 26Sell$404KIAN MORTIMERPRESIDENT & CEO↗
  • Mar 13, 26Sell$74KAndrea DiFabioChief Legal Officer↗
  • Mar 13, 26Sell$78KCHRISTOPHER JOHN KENNEYChief Medical Officer↗
  • Mar 10, 26Sell$677KIAN MORTIMERPRESIDENT & CEO↗
  • Mar 10, 26Sell$157KAndrea DiFabioChief Legal Officer↗

There are 9 more transactions in this stretch.

Stock compensation, tax and giftsshow the 19 other transactionshide

Stock compensation, tax withholding, option exercises and gifts. They are listed separately and are not included in the purchase and sale totals. The type describes the transaction, not the filer's intent.

  • Oct 15, 26Compensationamount n/aThomas Patrick KellyChief Financial Officer↗
  • Sep 1, 26Compensation$42KDawn Svoronos↗
  • Jun 1, 26Compensationamount n/aDawn Svoronos↗
  • Jun 1, 26Tax$76KDawn Svoronos↗
  • Jun 1, 26Compensationamount n/aGillian Cannon↗
  • Jun 1, 26Compensationamount n/aSTEVEN GANNON↗
  • Jun 1, 26Tax$76KSTEVEN GANNON↗
  • Jun 1, 26Compensationamount n/aELIZABETH A. GAROFALO↗
  • Jun 1, 26Compensationamount n/aJustin D. Gover↗
  • Jun 1, 26Compensationamount n/aPatrick Machado↗
  • Jun 1, 26Compensationamount n/aGARY PATOU↗
  • May 12, 26Compensation$26KSTEVEN GANNON↗
  • Mar 12, 26Compensationamount n/aIAN MORTIMERPRESIDENT & CEO↗
  • Mar 12, 26Compensationamount n/aAndrea DiFabioChief Legal Officer↗
  • Mar 12, 26Compensationamount n/aCHRISTOPHER JOHN KENNEYChief Medical Officer↗
  • Mar 9, 26Compensation$630KIAN MORTIMERPRESIDENT & CEO↗
  • Mar 9, 26Compensation$78KIAN MORTIMERPRESIDENT & CEO↗
  • Mar 9, 26Compensation$499KIAN MORTIMERPRESIDENT & CEO↗
  • Mar 9, 26Compensation$614KIAN MORTIMERPRESIDENT & CEO↗

The full record holds 134 transactions and goes back to Mar 7, 23.

Its sector and its market

Xenon Pharmaceuticals Inc. among Health Care companies

The profile shows what is on record. Context and Radar place the company among those of its sector and region.

With an account you also get

  • The four engines — growth, trend, risk and context — each with its word and its score.
  • The risk band and the sector phase.
  • The company's fundamentals and accounts.
  • Watchlist: your list of companies, with the «since you follow it» figure.

The research continues

The profile tells the story. The market sets the scene.

From Xenon Pharmaceuticals Inc., the path continues in the other areas. Each one is shown with its own example, named in its step.

  1. Place it in its market

    Seven layers of its region's market — rates, credit, stress, liquidity, regime, breadth and sectors — with historical precedents. Public example: Apple and ASML.

    See how Context works →
  2. See what deserves a closer look

    Every morning Radar screens the covered companies through a lens and explains why each candidate made the list. Public example: the lists from Aug 11, 2026.

    See how Radar works →
  3. Keep the why

    Follow Xenon Pharmaceuticals Inc. in the Watchlist and review what changed since you added it: context, notices and filings. Written theses are coming soon. Public example: Apple.

    See an example review →

Coverage

What sits behind this page.

Where each figure comes from and how far it reaches.

Prices
End-of-day closes provided by Twelve Data. One close per session; not real time. Closes adjusted for splits.
Series quality
Series with incidents in the period; the chart shows what could be kept.
SEC records
740 documents on file, from Sep 12, 2013 to Oct 16, 2026.
Company description
No description available.
This page
Generated on Oct 19, 2026; refreshed through the day.

Start at your own pace

Explore first. Go deeper with access.

Every company's public profile is open. The full reading — context, Radar, watchlist — is inside, in an invitation-only beta.

Compare plans →
  • No account

    This profile for every company we cover: closing prices with the record's facts on the curve, the SEC file in plain language, insider trades included, and links to its sector and exchange.

  • Pro

    What matters today, with its reason, is free with an account. Pro adds, in the profile, each company's notices and their explanation and the analysis of its insiders; in Radar, all the lenses, which notice each candidate carries, filters by notice type and «no dilution», and the cycle cohort filter; and in Watchlist, more companies and notice changes with their reason.

  • Pro+

    Adds the Lab: test a hypothesis on comparable cohorts before reusing it; and bring your lenses to Radar.

Are the prices real time?

No. It is one close per session, from the provider and with the date shown on the profile; it does not update during the trading day.

Which SEC documents appear here?

Those filed with the SEC by the company, its insiders and its major shareholders, within our coverage: periodic reports (10-K, 10-Q, 20-F), material events (8-K), proposed sale notices (Form 144), insider transactions (Form 4) and stakes above 5% (13D/13G). Each links to the original on EDGAR.

Why does a European company show no SEC records?

It depends on the company: some European issuers file a 20-F or 6-K with the SEC and others don't. The profile shows whatever is on record; when there is nothing, it says so rather than guessing why. Europe does not yet have a common filing archive like EDGAR in the United States. The EU will open its own, ESAP, in July 2027 (managers' transactions arrive in January 2028), and we plan to add it once it is available.

Before forming a view on a company,
read what is on record.

One close per session. The record in plain language. Its sector and its market one link away. Your judgment when deciding.

Access by invitation while the beta lasts. Not advice: the profile shows what is on record; it does not recommend.